L’outil de licence Creative Commons du formulaire de soumission ne fonctionne pas actuellement. Pour ajouter une licence CC à votre thèse ou publication, contactez ruor@uottawa.ca après le dépôt. -- The Creative Commons licence tool in the submission form is currently unavailable. To apply a CC licence to your thesis or publication, contact ruor@uottawa.ca after the deposit.

Comparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis

dc.contributor.authorGupta, Sana
dc.contributor.authorBell, Madison
dc.contributor.authorLiu, Laurel
dc.contributor.authorXiong, Grace
dc.contributor.authorAbu-Hilal, Mohannad
dc.date.accessioned2026-11-17T04:31:06Z
dc.date.issued2026-11-10
dc.date.updated2026-11-17T04:31:06Z
dc.description.abstractAbstract Introduction Despite the availability of several non-steroidal topical therapies for atopic dermatitis (AD), their comparative speed of clinical response remains unclear. This meta-analysis compared the efficacy of novel non-steroidal topical therapies for AD. Methods Four databases were searched for randomized controlled trials (RCTs) evaluating topical difamilast 1% twice daily (BID), tapinarof 1% once daily (QD), ruxolitinib 1.5% BID, roflumilast 0.05% or 0.15% QD in patients with AD. Outcomes included Investigator’s Global Assessment Treatment Success (IGA-TS) and 50%, 75% and 90% improvement in Eczema Area and Severity Index (EASI-50, EASI-75 and EASI-90) at weeks 1, 2, 4 and 8. Frequentist random-effects network meta-analyses estimated odds ratios (ORs) and 95% confidence intervals (CIs), primarily comprising indirect comparisons between non-steroidal topicals using a common vehicle comparator. Results Twenty-two RCTs (5843 participants) were included. Ruxolitinib demonstrated the highest odds of IGA-TS versus vehicle at week 2 (OR 8.94; 95% CI 5.28–15.12), 4 (OR 9.03; 95% CI 6.27–13.01) and 8 (OR 9.03; 95% CI 6.52–12.50), along with EASI-75 and EASI-90. Difamilast demonstrated favourable EASI-75 (OR 5.34; 95% CI 3.51–8.12) and EASI-90 (OR 6.71; 95% CI 3.79–11.89) responses versus vehicle at week 4; later data were unavailable. Conclusions Efficacy profiles varied across novel non-steroidal topical therapies, with ruxolitinib demonstrating the strongest and most consistent relative efficacy estimates. Response magnitude and timing remain important considerations when selecting topical AD treatments.
dc.identifier.urihttps://doi.org/10.1007/s13555-026-01968-8
dc.identifier.urihttp://hdl.handle.net/10393/52239
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleComparative Efficacy of Novel Non-steroidal Topical Therapies for Atopic Dermatitis: A Systematic Review and Network Meta-analysis
dc.typeJournal Article

Fichiers

Trousse originale

Voici les éléments 1 - 1 sur 1
En cours de chargement...
Vignette d'image
Nom:
13555_2026_Article_1968.pdf
Taille:
1.92 MB
Format:
Adobe Portable Document Format

Trousse de licence

Voici les éléments 1 - 1 sur 1
En cours de chargement...
Vignette d'image
Nom:
license.txt
Taille:
2.51 KB
Format:
Item-specific license agreed upon to submission
Description: